We work across key viral vector delivery systems including adeno-associated virus (AAV) to provide innovative solutions to cell and gene therapy biotechnology and biopharma companies.
We have built a sector leading lentiviral delivery system, LentiVector® platform which is already used in commercially available treatments.
Discover Oxford Biomedica – a quality and innovation-led viral vector CDMO with over 25 years of experience.
Get in touch
15 May 2023
05 May 2023
28 April 2023
Our viral vector platform is enabling our clients to bring next generation treatments for serious diseases to market.
Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.